Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stiefel, a GSK Company
With
GlaxoSmithKline
To investigate the development of microbial resistance when using one of two topical acne therapies for the treatment of moderate to moderately severe facial acne vulgaris. Clinical efficacy and tolerability will be assessed.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Outpatient at least 12 years of age. Female subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study.
Mild to moderate facial acne vulgaris
Able to understand the requirements of the study and sign informed consent/HIPAA authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.
You may not be if
Female subjects who are pregnant (positive urine pregnancy test), breast feeding or who are of childbearing potential and not practicing a reliable method of birth control
Allergy or sensitivity to any component of the test medication
Known hypersensitivity to to any component of the investigational formulations
Known history of enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis
Beards or sideburns
Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris
Evidence of recent alcohol or drug abuse
Participation in an investigational drug study within 30 days of the baseline visit
